Oric Pharmaceuticals, Inc. ORIC Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -41.3%+13.5pp | -54.7%-9.6pp | -45.1%-9.1pp | -36%-8.0pp | |
| Return on assets | -37.9%+10.7pp | -48.6%-8.3pp | -40.3%-7.7pp | -32.7%-6.3pp | |
| Return on invested capital | -53%+17.7pp | -70.7%-12.2pp | -58.5%+22.3pp | -80.8%— | |
| Liquidity | |||||
| Current ratio | 14.1×+3.6× | 10.6×+0.2× | 10.4×-3.3× | 13.7×-2.2× | |
| Quick ratio | 14.1×+3.6× | 10.6×+0.2× | 10.4×-3.3× | 13.7×-2.2× | |
| Cash ratio | 2.2×-0.2× | 2.4×+1.2× | 1.1×-3.2× | 4.3×-10.6× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $4.38+25.6% | $3.49-19.9% | $4.36-22.3% | $5.61-22.0% | |
| Valuation | |||||
| Market capitalization | $979.28M+23.4% | $569.48M+7.7% | $528.67M+123% | $236.68M-59.2% | |
| Enterprise value | $926.18M+23.9% | $519.43M+0.8% | $515.5M+183% | $181.94M-50.3% | |
| Price / book | 2.4×-1.3× | 2.3×0.0× | 2.4×+1.3× | 1.1×-1.1× | |
| Free cash flow yield | -11.4%+3.3pp | -20%-3.6pp | -16.4%+16.3pp | -32.6%-22.2pp | |
| Earnings yield | -13.8%+2.9pp | -22.5%-3.4pp | -19%+18.6pp | -37.7%-24.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Oric Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Oric Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.